Reduction of MicroRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C

Journal of Virology

Volumn 88, Issue 11, 2014, Pages 6394-6402

  Estrabaud, Emilie ^a,b,c,d   Lapalus, Martine ^a,b,c,d   Broët, Philippe ^e,f   Appourchaux, Kevin ^a,b,c,d   Muynck, Simon De ^a,b,c,d   Lada, Olivier ^a,b,c,d   Martinot Peignoux, Michelle ^a,b,c,d   Bièche, Ivan ^g   Valla, Dominique ^c   Bedossa, Pierre ^c   Marcellin, Patrick ^a,b,c,d   Vidaud, Michel ^g   Asselah, Tarik ^a,b,c,d  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

^d Laboratory of Excellence Labex INFLAMEX   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 122; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LAMBDA 3 INTERFERON GENE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAVIR SCORE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; VIRUS LOAD;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LINEAR MODELS; LIVER CIRRHOSIS; MICRORNAS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 84899855580     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00016-14     Document Type: Article

References (46)

1. Anonymous. 2004. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44:20-29. http://dx. doi. org/10. 1177/0091270003258669.
2. Marcellin P, Asselah T, Boyer N. 2002. Fibrosis and disease progression in hepatitis C. Hepatology 36:S47-S56. http://dx. doi. org/10. 1053/jhep. 2002. 36993.
3. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46. http://dx. doi. org/10. 1053/jhep. 2002. 36806.
4. Craxì A, Pawlotsky JM, Wedemeyer H, Bjoro K, Flisiak R, Forns X, Mondelli M, Peck-Radosavljevic M, Rosenberg W, Sarrazin C, Jacobson I, Dusheiko G, European Association for the Study of the Liver. 2011. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 55:245-264. http://dx. doi. org/10. 1016/j. jhep. 2011. 02. 023.
5. Asselah T, Marcellin P. 2013. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 33(Suppl 1):93-104. http://dx. doi. org/10. 1111/liv. 12076.
6. Asselah T, Marcellin P. 2014. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 34(Suppl 1):60-68.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401. http://dx. doi. org/10. 1038/nature08309.
8. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45:164-171. http://dx. doi. org/10. 1038/ng. 2521.
9. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R. 2013. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32:3055-3065. http://dx. doi. org/10. 1038/emboj. 2013. 232.
10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120-129. http://dx. doi. org/10. 1053/j. gastro. 2010. 04. 013.
11. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. 2012. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28Bunfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56:444-454. http://dx. doi. org/10. 1002/hep. 25647.
12. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297. http://dx. doi. org/10. 1016/S0092-8674(04)00045-5.
13. Meister G, Tuschl T. 2004. Mechanisms of gene silencing by double-stranded RNA. Nature 431:343-349. http://dx. doi. org/10. 1038/nature02873.
14. Gong BD, Xie Q, Xiang XG, Wang L, Zhao GD, An FM, Wang H, Lin LY, Yu H, Bao SS. 2010. Effect of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-bearing Huh7 cells. Int. J. Mol. Med. 25:853-859.
15. Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD, Proll S, Katze MG. 2009. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 10:373. http://dx. doi. org/10. 1186/1471-2164-10-373.
16. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. 2009. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49:1098-1112. http://dx. doi. org/10. 1002/hep. 22749.
17. Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K. 2010. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med. Genomics 3:48. http://dx. doi. org/10. 1186/1755-8794-3-48.
18. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjarn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S. 2008. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36:1153-1162. http://dx. doi. org/10. 1093/nar/gkm1113.
19. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3:87-98. http://dx. doi. org/10. 1016/j. cmet. 2006. 01. 005.
20. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. 2008. miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 48:648-656. http://dx. doi. org/10. 1016/j. jhep. 2008. 01. 019.
21. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581. http://dx. doi. org/10. 1126/science. 1113329.
22. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201. http://dx. doi. org/10. 1126/science. 1178178.
23. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. 2013. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368:1685-1694. http://dx. doi. org/10. 1056/NEJMoa1209026.
24. Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K, Matsuura Y. 2012. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with HCV. J. Virol. 86:7918-7933. http://dx. doi. org/10. 1128/JVI. 00567-12.
25. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, Matsuura Y. 2012. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J. Virol. 86:1382-1393. http://dx. doi. org/10. 1128/JVI. 06242-11.
26. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15:31-33. http://dx. doi. org/10. 1038/nm. 1902.
27. Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, Chen PJ, Kao JH, Chen DS. 2013. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc. Natl. Acad. Sci. USA. 110:7844-7849. http://dx. doi. org/10. 1073/pnas. 1306138110.
28. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Mullhaupt B, Gerlach T, Heim MH, Moradpour D, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgiewski M, Bourliere M, Poynard T, Theodorou I, Abel L, Pol S, Dufour JF, Negro F. 2012. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55: 384-394. http://dx. doi. org/10. 1002/hep. 24678.
29. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. 2011. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54: 1127-1134. http://dx. doi. org/10. 1002/hep. 24503.
30. Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner DE, Liang TJ, Ghany MG. 2013. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58:1548-1557. http://dx. doi. org/10. 1002/hep. 26506.
31. Li J, Ghazwani M, Zhang Y, Lu J, Fan J, Gandhi CR, Li S. 2013. miR-122 regulates collagen production via targeting hepatic stellate cells and sup-pressing P4HA1 expression. J. Hepatol. 58:522-528. http://dx. doi. org/10. 1016/j. jhep. 2012. 11. 011.
32. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. 2013. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J. Hepatol. 58:234-239. http://dx. doi. org/10. 1016/j. jhep. 2012. 10. 015.
33. Asselah T, Bieche I, Laurendeau I, Martinot-Peignoux M, Paradis V, Vidaud D, Valla DC, Bedossa P, Marcellin P, Vidaud M. 2008. Significant gene expression differences in histologically "Normal" liver biopsies: implications for control tissue. Hepatology 48:953-962. http://dx. doi. org/10. 1002/hep. 22411.
34. Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, Marcellin P, Vidaud M. 2005. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 332:130-144. http://dx. doi. org/10. 1016/j. virol. 2004. 11. 009.
35. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, Marcellin P. 2005. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064-2075. http://dx. doi. org/10. 1053/j. gastro. 2005. 09. 010.
36. Asselah T, De Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, El Ray A, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P. 2012. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 56:527-532. http://dx. doi. org/10. 1016/j. jhep. 2011. 09. 008.
37. Estrabaud E, Vidaud M, Marcellin P, Asselah T. 2012. Genomics and HCVinfection: progression of fibrosis and treatment response. J. Hepatol. 57:1110-1125. http://dx. doi. org/10. 1016/j. jhep. 2012. 05. 016.
38. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB. 2011. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53:336-345. http://dx. doi. org/10. 1002/hep. 24052.
39. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. 2012. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 142: 78-85. http://dx. doi. org/10. 1053/j. gastro. 2011. 09. 039.
40. Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR. 2011. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J. Mol. Diagn. 13:446-451. http://dx. doi. org/10. 1016/j. jmoldx. 2011. 03. 008.
41. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S. 2008. LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899. http://dx. doi. org/10. 1038/nature06783.
42. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888-1896. http://dx. doi. org/10. 1002/hep. 23912.
43. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922. http://dx. doi. org/10. 1038/nature06205.
44. Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K. 2012. Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. Sci. Rep. 2:637. http://dx. doi. org/10. 1038/srep00637.
45. Everhart JE, Wright EC. 2013. Association of gamma-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology 57:1725-1733. http://dx. doi. org/10. 1002/hep. 26203.
46. Friedman SL. 2010. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7:425-436. http://dx. doi. org/10. 1038/nrgastro. 2010. 97.